Combining CAR‐T cell treatment with immune checkpoint inhibition (e.g., blocking antibodies of PD‐1/PD‐L1 and CTLA‐4) has been shown to impact tumour immunosuppressive forces and anticancer activity212, 213 significantly. This evidence concerns the gene CTLA4 and neoplasm.